Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

SZLS.TO Relative to the S&P 500

SZLS.TO Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the StageZero Life Sciences Ltd (TSE:SZLS.TO) seasonal charts above shows that a Buy Date of December 5 and a Sell Date of March 4 has resulted in a geometric average return of 22.18% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 13 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 53.8% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

StageZero Life Sciences Ltd is a Canadian company, focused on developing and commercializing proprietary molecular diagnostic tests for early detection of diseases and personalized health management, with a primary focus on cancer-related indications. It develops a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. Its lead product, ColonSentry is a blood test to determine the patient’s current risk of having colorectal cancer.

To download SZLS.TO seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: SZLS.TO